Skip to main content
. 2016 Aug 2;157(11):2605–2616. doi: 10.1097/j.pain.0000000000000681

Figure 8.

Figure 8.

System xc can be targeted directly or indirectly to reduce glutamate in the bone-tumor microenvironment and assuage cancer-induced bone pain (CIBP). System xc can be targeted pharmacologically through direct blockage with sulfasalazine or through elimination of peroxynitrite with the decomposition catalysts FeTMPyP and SRI10. Both therapeutic strategies reduced glutamate in the bone–tumor microenvironment and CIBP-related behaviors.